Wow. Novo wasn’t just the sponsor here. They designed the protocol, ran the trial, analyzed the data, and co-wrote (at a minimum) the paper. Did NEJM have the decency to at least use different font and label it as an infomercial?
This is no different than the StepHFpEF studies….if you lose 11% of body weight (average about 20 lbs), your s…
Wow. Novo wasn’t just the sponsor here. They designed the protocol, ran the trial, analyzed the data, and co-wrote (at a minimum) the paper. Did NEJM have the decency to at least use different font and label it as an infomercial?
This is no different than the StepHFpEF studies….if you lose 11% of body weight (average about 20 lbs), your soft endpoints like QoL are gonna get better. Doesn’t make it a disease-modifying HFpEF drug. And similarly here, starting from a BMI of 40, it’s hardly shocking that losing a bunch of weight would improve joint symptoms.
Maybe they should do a study of the effect of Semaglutide on pant sizes. I’m guessing they can show that sema causally reduces pant sizes too.
It is truly a face-palm that something like this could end up in NEJM.
Wow. Novo wasn’t just the sponsor here. They designed the protocol, ran the trial, analyzed the data, and co-wrote (at a minimum) the paper. Did NEJM have the decency to at least use different font and label it as an infomercial?
This is no different than the StepHFpEF studies….if you lose 11% of body weight (average about 20 lbs), your soft endpoints like QoL are gonna get better. Doesn’t make it a disease-modifying HFpEF drug. And similarly here, starting from a BMI of 40, it’s hardly shocking that losing a bunch of weight would improve joint symptoms.
Maybe they should do a study of the effect of Semaglutide on pant sizes. I’m guessing they can show that sema causally reduces pant sizes too.
It is truly a face-palm that something like this could end up in NEJM.